These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 33813274)
21. In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease. Sur VP; Sen MK; Komrskova K Molecules; 2021 Oct; 26(20):. PubMed ID: 34684780 [TBL] [Abstract][Full Text] [Related]
22. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. Deshmukh MG; Ippolito JA; Zhang CH; Stone EA; Reilly RA; Miller SJ; Jorgensen WL; Anderson KS Structure; 2021 Aug; 29(8):823-833.e5. PubMed ID: 34161756 [TBL] [Abstract][Full Text] [Related]
23. Docking Paradigm in Drug Design. Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135 [TBL] [Abstract][Full Text] [Related]
24. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA Viruses; 2021 Jan; 13(2):. PubMed ID: 33503819 [TBL] [Abstract][Full Text] [Related]
25. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV. Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605 [TBL] [Abstract][Full Text] [Related]
26. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092 [TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 M Rut W; Groborz K; Zhang L; Sun X; Zmudzinski M; Pawlik B; Wang X; Jochmans D; Neyts J; Młynarski W; Hilgenfeld R; Drag M Nat Chem Biol; 2021 Feb; 17(2):222-228. PubMed ID: 33093684 [TBL] [Abstract][Full Text] [Related]
28. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses. Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977 [TBL] [Abstract][Full Text] [Related]
29. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2. Yassine R; Makrem M; Farhat F Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259 [TBL] [Abstract][Full Text] [Related]
30. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760 [TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome. Sardanelli AM; Isgrò C; Palese LL Molecules; 2021 Mar; 26(5):. PubMed ID: 33807773 [TBL] [Abstract][Full Text] [Related]
32. Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors. Jiao Z; Yan Y; Chen Y; Wang G; Wang X; Li L; Yang M; Hu X; Guo Y; Shi Y; Peng G J Virol; 2022 Sep; 96(17):e0090722. PubMed ID: 36000844 [TBL] [Abstract][Full Text] [Related]
33. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2. Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738 [TBL] [Abstract][Full Text] [Related]
35. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing. Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194 [TBL] [Abstract][Full Text] [Related]
36. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization. Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704 [TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267 [TBL] [Abstract][Full Text] [Related]
38. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Bai Y; Ye F; Feng Y; Liao H; Song H; Qi J; Gao GF; Tan W; Fu L; Shi Y Signal Transduct Target Ther; 2021 Feb; 6(1):51. PubMed ID: 33542181 [No Abstract] [Full Text] [Related]
39. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884 [TBL] [Abstract][Full Text] [Related]
40. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics. Alhadrami HA; Sayed AM; Sharif AM; Azhar EI; Rateb ME Molecules; 2021 May; 26(9):. PubMed ID: 34062737 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]